On air · 1 of 3 networks
Nextcea, Inc. ads
- nextcea.com
- Biotechnology Research
- US
- 5 employees
Nextcea, Inc.’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 31. Watch Nextcea, Inc. on any plan to get each new one in your feed.
Watchlist included in every plan
What Nextcea, Inc. runs
- Single image · LinkedIn
- 6
- Google ads on 4 Nov 2026
- 9
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksNov 2026 | Checked | Next step |
|---|---|---|---|---|---|
| None recorded | 0 | Checked 7 Nov 2026 | See all 31 ads → | ||
| Meta | Not checked | — | |||
| Running | 9 | Ads on the Google Ads Transparency Center | Checked 4 Nov 2026 | Collect them with the API → |
Nextcea, Inc. has no live LinkedIn ads. We recorded 9 Google ads on 4 Nov 2026.
Latest ads
- LINKEDIN · IMAGESince 24 Aug 2026
Nextcea specializes in DIPL bioassay services for non-clinical and clinical studies. We provide GLP validated bioanalytical LC-MS/MS methods for measurement of non-invasive di-22:6-BMP in animal and human matrices (urine) using our patented biomarker. Visit our website to learn more!
- LINKEDIN · IMAGESince 17 Aug 2026
At Nextcea, we turn complex biomarker data into actionable development strategy. Using advanced LC‑MS/MS 7500, GLP/GCP‑compliant workflows, we help you link biomarker changes directly to efficacy and safety outcomes—so you can accelerate timelines without compromising quality. Visit our website to learn more.
- LINKEDIN · IMAGESince 10 Aug 2026
Innovation starts with better biomarkers. Nextcea's patented di-22:6-BMP biomarker, powered by our state-of-the-art LC-MS/MS platform, provides enhanced efficacy evaluations for LRRK2 inhibitors in both non-clinical and clinical trials. Discover how our technology can strengthen your research and development strategy. Visit our website to learn more.
- LINKEDIN · IMAGESince 3 Aug 2026
You shouldn’t have to choose between efficacy insight and safety clarity. Nextcea’s biomarker-driven platform unifies drug efficacy andsafety, powered by LC‑MS/MS 7500 technology. We help pharma, biotech, and academic teams zero in on optimal doses, reduce toxicity risk, and advance candidates with confidence. Learn more on our website!
- LINKEDIN · IMAGESince 27 Jul 2026
You need to know not just if a drug works, but why—and how safely. We provide integrated LC‑MS/MS biomarker quantitation with our patented biomarker di-22:6 BMP ensuring every data point informs your development strategy. From exploratory non-GLP work to regulated GLP/GCP studies, Nextcea helps you design smarter, more successful trials. Visit our website to learn more!
- LINKEDIN · IMAGERecorded 27 Sept 2026
At Nextcea, we understand the critical need for precision in studying Parkinson's and Gaucher Diseases. Our GBA1 solution offers ultra-sensitive detection of GCase activity and lipid biomarkers, ensuring unparalleled accuracy. With our innovative Gmetry substrate technology, you can achieve specific insights into disease pathways to drive your research forward. Visit our website to learn more!
6 of 31 adsSign up to see every Nextcea, Inc. ad, filter by format and date, and get alerts on new ones.
See all 31 adsQuestions about Nextcea, Inc.’s ads
Is Nextcea, Inc. running LinkedIn ads?
We recorded no live LinkedIn ads for Nextcea, Inc. on 10 Nov 2026.
How many LinkedIn ads has Nextcea, Inc. run?
LinkedIn’s ad library lists 31 ads for Nextcea, Inc.. We recorded 31 LinkedIn ads for Nextcea, Inc., first recorded on 27 Sept 2026 and last recorded on 27 Sept 2026.
Does Nextcea, Inc. run Google ads?
Yes. We recorded 9 Google ads for the domain nextcea.com on 4 Nov 2026.
Which ad formats does Nextcea, Inc. use?
The 6 LinkedIn ads on this page include 6 image ads.
Watch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.